The Semel Institute for Neuroscience and Human Behavior is a research institute of the University of California Los Angeles.

During the past decade, UCLA Semel Institute conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 15 clinical trials were completed, i.e. on average, 53.6% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 10 clinical trials were completed. i.e. 90.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA Semel Institute" #1 sponsor was "University of California, Los Angeles" with 46 trials, followed by "Seaside Therapeutics, Inc." with 9 trials sponsored, "National Institute of Mental Health (NIMH)" with 3 trials sponsored, "Think Now Incorporated" with 3 trials sponsored and "Ann & Robert H Lurie Children's Hospital of Chicago" with 3 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Semel Institute" #1 collaborator was "National Institute of Mental Health (NIMH)" with 20 trials as a collaborator, "University of California, Los Angeles" with 7 trials as a collaborator, "Janssen Scientific Affairs, LLC" with 3 trials as a collaborator, "Wyeth is now a wholly owned subsidiary of Pfizer" with 3 trials as a collaborator and "Forest Laboratories" with 2 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "UCLA Semel Institute" are "Depression" (9 trials), "Major Depressive Disorder" (8 trials), "Schizophrenia" (6 trials), "Fragile X Syndrome" (5 trials) and "Attention Deficit Hyperactivity Disorder (ADHD)" (4 trials). Many other conditions were trialed in "UCLA Semel Institute" in a lesser frequency.

Most popular intervention types in "UCLA Semel Institute" are "Drug" (42 trials), "Behavioral" (21 trials), "Device" (7 trials), "Other" (7 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Escitalopram" (4 trials), "Arbaclofen" (3 trials), "STX209" (3 trials) and "Active TNS" (2 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Semel Institute" are 73 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are 14 active trials in "UCLA Semel Institute". 2 are not yet recruiting, 8 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 51 completed trials in UCLA Semel Institute, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Semel Institute, 3 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 17 trials, and there were also 29 trials that are defined as “Not Applicable".